Skip to main content

Table 1 Baseline characteristics of the NSCLC patients with EGFR 19delins or EGFR 19del

From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

  Characteristics 19delins (n = 41) 19del (n = 41) P value
Age, years Median (range) 60 (30–75) 60 (34–76) 0.638
Sex Male 17 11 0.162
Female 24 30  
Smoking status Never 34 34 1.000
Smoker 7 7  
Histological type Adenocarcinoma 40 41 1.000
Squamous carcinoma 1 0  
TNM stage IIIB 0 0 1.000
IV 41 41  
ECOG PFS score 0 or 1 34 31 0.414
2 7 10  
Brain metastases No 25 27 0.647
Yes 16 14  
EGFR 19delins variants p.L747_P753delinsS 10   
p.L747_A750delinsP 9   
p.L747_T751delinsP 6   
p.E746_S752delinsV 3   
Other EGFR 19delins 13   
EGFR 19del variants p.E746_A750del   36  
p.L747_S752del   3  
P.L747_T751del   2  
First-line treatment Gefitinib 24 25 0.973
Icotinib 15 14  
Erlotinib 2 2  
  1. 19delins, EGFR exon 19 deletion-insertion; 19del, EGFR exon 19 deletion; ECOG PS Eastern Cooperative Oncology Group performance status